NICE recommends PCSK9 inhibitors for patients not responding to statinsBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2609 (Published 09 May 2016) Cite this as: BMJ 2016;353:i2609
- Susan Mayor
The National Institute for Health and Care Excellence (NICE) has recommended the PCSK9 inhibitors alirocumab and evolocumab for patients with primary hypercholesterolaemia or mixed dyslipidaemia that is not controlled with statins, in final draft guidance based on manufacturers providing the drugs at discounted prices.
The drugs are monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9), which slows the degradation of low density lipoprotein receptors in the liver. This helps to reduce levels of low density lipoprotein (LDL) cholesterol.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial